BLM treatment significantly increased malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) levels while reducing GSH and GPX4 levels and HO-1 activity in the BLM-treated group compared to the control and EMPA-treated groups. Here, GPX4 is linked to Bloom syndrome.